Inactive Instrument

American CryoStem Corporation

Equities

CRYO

US0253001046

Biotechnology & Medical Research

American Cryostem Corporation Auditor Raises 'Going Concern' Doubt

January 15, 2013 at 03:50 am IST

American Cryostem Corporation filed its 10-K on Jan 14, 2013 for the period ending Sep 30, 2012. In this report its auditor, Donahue Associates, L.L.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about American CryoStem Corporation

American CryoStem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	23/22/23	CI
American CryoStem Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	24/22/24	CI
American CryoStem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2021	23/22/23	CI
American CryoStem Corporation Reports Earnings Results for the Full Year Ended September 30, 2021	14/22/14	CI
American CryoStem Corporation Auditor Raises 'Going Concern' Doubt	13/22/13	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2021	24/21/24	CI
American Cryostem Corporation Reports Earnings Results for the Second Quarter Ended March 31, 2021	18/21/18	CI
American Cryostem Corporation Reports Earnings Results for the Full Year Ended September 30, 2020	09/21/09	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2020	19/20/19	CI
American Cryostem Corporation Reports Earnings Results for the Second Quarter Ended March 31, 2020	21/20/21	CI
American Cryostem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2019	20/20/20	CI
American Cryostem Corporation Reports Earnings Results for the Full Year Ended September 30, 2019	15/20/15	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2019	20/19/20	CI
American Cryostem Corporation Reports Earnings Results for the Second Quarter Ended March 31, 2019	21/19/21	CI
American CryoStem Corporation Completes Cooperative Framework Agreement to Expand Market Presence in Japan	21/19/21	CI
American Cryostem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2018	19/19/19	CI
American CryoStem Corporation Enters into Agreement to License its Patented Adipose Tissue and Stem Cell Technologies in Thailand	05/18/05	CI
American CryoStem Corporation Secures Major Contract in Mainland China	25/17/25	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2017	22/17/22	CI
American Cryostem Corporation Reports Revenue Results for the Year Ended September 30, 2016	04/17/04	CI
American CryoStem Corporation Expands with the Opening of New Lab Facility in Princeton, NJ	06/16/06	CI
American Cryostem Corporation Auditor Raises 'Going Concern' Doubt	13/16/13	CI
American Cryostem Corporation Signs Licensing Agreement with Cell Source	23/15/23	CI
American Cryostem Corporation acquired certain assets of BioLife Cell Bank, Inc.	20/15/20	CI
American Cryostem Corporation Auditor Raises 'Going Concern' Doubt	20/15/20	CI

Chart American CryoStem Corporation

Duration

Period

More charts

Company Profile

American CryoStem Corporation is a biotechnology company. The Company has developed adipose tissue-derived technologies (Adult Stem Cells) for the fields of regenerative and personalized medicine. Its technologies are the basis for the chemistry, manufacturing, and controls (cGMP Manufacturing) of its ATCell autologous cellular therapy product for use in clinical investigations for biologic license applications with the United States Food and Drug Administration (FDA). The Company has developed and refined its pipeline around its cellular product, ATCell, for clinical therapeutic use. The Companyâs ATCELL cell lines are cultured in its patented ACSelerate cell culture media. Its CELLECT service is the required platform for the collection and transportation of live adipose tissue samples to its processing facility. Its ACSelerate cell culture media products are manufactured using patented cell culture media for growing human stromal cells. The Company also includes ATGRAFT services.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research